56Curated trials
Enterprise Evidence Report · NR-REPORT-V2.0
Bulgaria
Neuroscience Intelligence
Bulgaria neuroscience evidence report: current clinical, research, institution and source-linked intelligence.
Evidence rank #43 of 50 · Data maturity A · Research score 28.6 · Data confidence 100.0 / 100 · Snapshot 2026-10-12 03:36 UTC.
14Recruiting trials
4Publications
15Institutions
Executive interpretation
Bulgaria ranks #43 in the current NeuroRisk evidence-ranked market layer. This ranking summarizes indexed clinical, publication and institution evidence; it is not a probability of commercial success and not an investment recommendation.
Methodology status
Methodology NR-REPORT-V2.0. No synthetic ML confidence is presented as scientific probability. Counts and source links below are tied to the generation snapshot.
Methodology →Leading sponsors
Novo Nordisk A/S41 recruiting
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.30 recruiting
AbbVie30 recruiting
Pfizer30 recruiting
Bayer22 recruiting
H. Lundbeck A/S20 recruiting
Hoffmann-La Roche20 recruiting
Boehringer Ingelheim20 recruiting
Celgene20 recruiting
Supernus Pharmaceuticals, Inc.21 recruiting
Disease activity
Epilepsy11trials
Parkinsons6trials
Multiple Sclerosis5trials
Alzheimers5trials
Depression4trials
Schizophrenia3trials
Other Psychiatry2trials
Bipolar Disorder2trials
Traumatic Brain Injury1trials
Anxiety1trials
Research institutions
University Hospital St. Ivan RilskiOpenAlexlinked institution
Institute of NeurobiologyOpenAlexlinked institution
Institute of Molecular BiologyOpenAlexlinked institution
Alexandrovska HospitalOpenAlexlinked institution
National Heart HospitalOpenAlexlinked institution
National Center of Public Health and AnalysesOpenAlexlinked institution
Stephan Angeloff Institute of MicrobiologyOpenAlexlinked institution
Military Medical AcademyOpenAlexlinked institution
Medical University PlovdivOpenAlexlinked institution
New Bulgarian UniversityOpenAlexlinked institution
Clinical evidence trail
NCT07743580A Study of Secutrelvir in Participants With Coronavirus Disease 2019 (COVID-19) Who Are at High Risk for Progression to Severe DiseaseRECRUITING
NCT07011732A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)RECRUITING
NCT06887192A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease PsychosisRECRUITING
NCT06798896RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset SeizuresRECRUITING
NCT06701903Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety DisorderRECRUITING
NCT06290128A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not WorkACTIVE_NOT_RECRUITING
NCT05980949Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)RECRUITING
NCT05973773REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)ACTIVE_NOT_RECRUITING
NCT05667142A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic SeizuresRECRUITING
NCT05567796A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose WeightACTIVE_NOT_RECRUITING
NCT05457283A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and ProteinuriaRECRUITING
NCT05239728A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)ACTIVE_NOT_RECRUITING
Research evidence trail
PUBMEDA simple method for identifying latent spasticity following compressive spinal cord injury by provoking clonic contractions of the hindpaw- and back musculature in rats.2026-10-01
PUBMEDClinical heterogeneity and diagnostic challenges in CASK-related neurodevelopmental disorders: a longitudinal observational study.2026-01-01
PUBMEDVariant Ataxia-Telangiectasia Presenting as Tremor-Dystonia Syndrome in a Bulgarian Religious Minority.2025-05-27
Sources and provenance
ClinicalTrials.gov provides NCT evidence. PubMed/NCBI and OpenAlex provide research metadata. OpenAlex links institutions. World Bank indicators are included only when an explicit source row and year exist. NeuroRisk transformations add normalization, ranking and graph connections.
Limitations
Indexed corpus counts are not guaranteed exhaustive global totals. Scores are comparative decision-support signals. This report is not medical advice, regulatory advice, patent clearance, an investment recommendation or a guarantee of outcome.